Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, announced the pricing of an underwritten public offering of 9,669,631 shares of common stock at a price of $27.80 per share, and pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant. The offering is set to gross Mirati a total of $300.0 million, before deducting underwriting discounts and estimated offering expenses. The offering is expected to close on or around August 11, 2023, and an additional 1,618,705 shares of common stock may be purchased by underwriters within a 30-day option.
Goldman Sachs & Co. LLC is taking the lead in a proposed offering, acting as the book-running manager, while Leerink Partners LLC has been recruited as the financial advisor. This offering has the potential to be a game changer, and both Goldman Sachs and Leerink Partners are determined to ensure it is a success.
Mirati has filed a shelf registration statement with the Securities and Exchange Commission, which has become automatically effective on filing. If you would like to learn more about this offering, you can obtain the preliminary prospectus supplement and accompanying prospectus from Goldman Sachs & Co. LLC. Just contact them through telephone , by email at prospectus
Don’t miss your chance to invest in these exciting securities! This once-in-a-lifetime opportunity may not be available in all states or jurisdictions, so act now before it’s too late. There will be no offers to sell or solicitations to buy these securities before the registration or qualification under the securities laws of any such state or other jurisdiction.
About Mirati Therapeutics, Inc.
At Mirati Therapeutics, our mission is to save lives with cancer by developing revolutionary treatment options and giving hope to those affected. We are dedicated to discovering, designing, and delivering a range of therapies to treat the most crucial unmet needs for cancer patients, particularly in the area of lung cancer. Our goal is to use the latest genetic and immunological advances to provide the best possible outcomes for our patients and their families, with a vision of a life beyond cancer for every individual.
Mirati Technologies is proud to announce its upcoming public offering of securities, and is hopeful that the expected completion and timing of the offering will be up to expectations. However, no assurances can be made, and investors should be aware of the risks and uncertainties associated with the offering, which may cause actual results to differ materially from those anticipated.
Risks and uncertainties can include market fluctuations and the satisfaction of customary closing conditions of the offering, but Mirati Technologies will do everything in its power to ensure the completion and timing of the offering is met as expected.